Abstract
Aims/hypothesis
Adipose tissue (AT) distribution is a major determinant of mortality and morbidity in obesity. In mice, intra-abdominal transplantation of subcutaneous AT (SAT) protects against glucose intolerance and insulin resistance (IR), but the underlying mechanisms are not well understood.
Methods
We investigated changes in adipokines, tissue-specific glucose uptake, gene expression and systemic inflammation in male C57BL6/J mice implanted intra-abdominally with either inguinal SAT or epididymal visceral AT (VAT) and fed a high-fat diet (HFD) for up to 17 weeks.
Results
Glucose tolerance was improved in mice receiving SAT after 6 weeks, and this was not attributable to differences in adiposity, tissue-specific glucose uptake, or plasma leptin or adiponectin concentrations. Instead, SAT transplantation prevented HFD-induced hepatic triacylglycerol accumulation and normalised the expression of hepatic gluconeogenic enzymes. Grafted fat displayed a significant increase in glucose uptake and unexpectedly, an induction of skeletal muscle-specific gene expression. Mice receiving subcutaneous fat also displayed a marked reduction in the plasma concentrations of several proinflammatory cytokines (TNF-α, IL-17, IL-12p70, monocyte chemoattractant protein-1 [MCP-1] and macrophage inflammatory protein-1β [ΜIP-1β]), compared with sham-operated mice. Plasma IL-17 and MIP-1β concentrations were reduced from as early as 4 weeks after transplantation, and differences in plasma TNF-α and IL-17 concentrations predicted glucose tolerance and insulinaemia in the entire cohort of mice (n = 40). In contrast, mice receiving visceral fat transplants were glucose intolerant, with increased hepatic triacylglycerol content and elevated plasma IL-6 concentrations.
Conclusions/interpretation
Intra-abdominal transplantation of subcutaneous fat reverses HFD-induced glucose intolerance, hepatic triacylglycerol accumulation and systemic inflammation in mice.
Similar content being viewed by others
Introduction
Adipose tissue (AT) distribution is a major determinant of mortality and morbidity in obesity [1]. Specifically, accumulation of intra-abdominal or visceral AT (VAT) is associated with type 2 diabetes, dyslipidaemia and hypertension [2]. This relationship was originally attributed to increased NEFA flux from VAT into the portal circulation [3]. However, VAT makes only a minor contribution to portal NEFA concentrations [4], suggesting that other factors, such as adipokines [5], are also involved.
Independently of VAT, greater amounts of subcutaneous AT (SAT), particularly in the lower body, may protect against glucose intolerance, insulin resistance (IR), dyslipidaemia and atherosclerosis [6]. Gluteal–femoral SAT, for example, prevents lipotoxicity in non-adipose tissues by sequestering meal-derived NEFA [7, 8], and resists deleterious gene expression changes in obesity [9]. Understanding how different AT depots influence the risk of glucose intolerance, IR and dyslipidaemia may yield new therapeutic targets for metabolic disease [10].
Obesity and IR are characterised by chronic inflammation [11], with elevated proinflammatory cytokine production in AT [12]. Adipocyte hypertrophy in AT is accompanied by macrophage infiltration [13] and polarisation towards a classically activated proinflammatory (M1) type rather than ‘alternatively’ activated, anti-inflammatory macrophages (M2) [14]. Proinflammatory cytokines impair insulin action both locally and in other tissues, such as liver [15]. AT from obese, insulin-resistant humans also has a higher proinflammatory T cell content [16]. Anti-inflammatory treatment improves glycaemic control in humans with type 2 diabetes [17].
We and others have investigated the relationship between regional adiposity and metabolism by performing syngeneic AT transplantation in mice [18–22]. Intra-abdominal transplantation of epididymal AT was initially reported to improve glucose tolerance and reduce insulinaemia within 4–8 weeks [18]. In mice fed a high-fat diet (HFD) for 13 weeks, however, we found that intra-abdominal transplantation of inguinal AT, but not epididymal AT, improved glucose tolerance and reduced adiposity [19]. This did not occur when inguinal AT was transplanted subcutaneously. Our findings were confirmed by Tran et al [20], who also reported differences in AT glucose uptake between mice receiving intra-abdominal AT transplants and sham-operated mice, under euglycaemic–hyperinsulinaemic clamp conditions. More recently, intra-abdominal transplantation of either inguinal or epididymal AT has been reported to reverse HFD-induced glucose intolerance and liver triacylglycerol accumulation within 4 weeks [21].
We aimed to address these discrepancies and identify the underlying mechanisms. While the beneficial effects of inguinal SAT transplantation on glucose tolerance are highly reproducible [19–22], epididymal AT transplantation is linked with both beneficial [18, 21] and negligible [19, 20] effects on metabolism, relative to sham-operated mice. Therefore, we performed time course studies to investigate the short- and long-term effects of inguinal subcutaneous → visceral (SubQ → Vis) and epididymal visceral → visceral (Vis → Vis) AT transplantation in HFD-fed mice.
Methods
Animals and surgery
Six-week-old male C57BL6/J mice were obtained from Australian Bioresources (Moss Vale, NSW, Australia) and housed as described previously [23]. Studies were approved by the Garvan Institute/St Vincent’s Hospital Animal Experimentation Ethics Committee, and were performed according to guidelines set by the National Health and Medical Research Council of Australia.
Inguinal and epididymal AT depots were dissected out from donors and transplanted into anaesthetised recipient littermates via a midline incision. AT was sutured onto the peritoneal surface of the anterior abdominal wall using Vicryl 4-0 sutures (Ethicon, Somerville, NJ, USA). The incision was closed with wound clips. Sham-operated mice received identical surgical treatment without transplant. After regaining their pre-surgical weight, mice were provided ad libitum with either chow (8% of energy from fat, Gordon’s Specialty Stock Feeds, Yanderra, NSW, Australia) or HFD (45% of energy from fat, based on D12451, Research Diets, New Brunswick, NJ, USA). At the end of the experiment, mice were killed by cervical dislocation.
Body composition, respirometry and food intake
Body composition was measured by dual-energy x-ray absorptiometry (DEXA; Lunar PIXImus, GE Medical Systems, New York, NY, USA) under isoflurane anaesthesia. Twelve weeks after transplantation, food intake, energy expenditure and RQ were measured as described previously [23].
Glucose and insulin tolerance tests
Intraperitoneal glucose tolerance tests (GTTs; 2 g/kg) were performed in conscious 6-h-fasted mice. For insulin tolerance tests (ITTs), mice were fasted for 4 h before injection of 0.75 U/kg body weight i.p. (Actrapid, Novo Nordisk, Baulkham Hills, NSW, Australia). Blood glucose concentrations were measured using an Accu-Chek meter (Roche Diagnostics, Castle Hill, NSW, Australia).
For measurement of tissue-specific glucose uptake, 6-h-fasted mice were injected with 1.5 g/kg glucose containing tracer amounts of [U-14C]glucose (370,000 Bq/mouse) and [3H-2]deoxyglucose (37,000 Bq/mouse; Perkin-Elmer, Glen Waverley, VIC, Australia). Tail blood was collected into heparinised tubes (Microvette CB300LH, Sarstedt, Mawson Lakes, SA, Australia), and plasma was separated by centrifuging at 2,000×g for 5 min. Glucose uptake in skeletal muscle and individual AT depots was normalised for the specific activity of glucose in plasma as described previously [24].
AT adipocyte sizing and immunohistochemistry
Tissues were fixed in 3.7% (vol./vol.) formaldehyde, paraffin-embedded, cut into 4 μm sections and stained with haematoxylin and eosin. Adipocyte size was determined in three representative fields from each section (100-150 adipocytes/field) using ImageJ software (National Institutes of Health, USA). Adipocyte size distribution was determined for each depot by assigning adipocytes to 500 μm2 bins. Differences between groups were determined by χ 2 test. Graft apoptosis was assessed by cleaved caspase-3 immunohistochemistry [25].
Biochemical methods
Tissue triacylglycerol and glycogen content, and plasma insulin and NEFA concentrations were measured as described [23]. Plasma leptin and adiponectin concentrations were measured by ELISA (Crystal Chem, Downers Grove, IL, USA and R&D Systems, Minneapolis, MN, USA, respectively). Plasma lactate was measured using a YSI 2300 Analyzer (YSI Life Sciences, Yellow Springs, OH, USA).
Microarrays
Tissues were obtained in our previous 13 week study [19], which included mice receiving subcutaneous inguinal AT in the dorsal subcutaneous space (SubQ → SubQ). RNA was extracted from the following depots (n = 5 of each): SubQ → Vis and SubQ → SubQ grafts, endogenous inguinal SAT from SubQ → Vis mice (SubQ → Vis ING), endogenous epididymal AT from SubQ → Vis mice (SubQ → Vis EPI) and inguinal SAT from a sham-operated mouse (Sham ING).
cDNA preparation and array hybridisation were performed according to the manufacturer’s instructions (Affymetrix Mouse Genome 430 2.0, Santa Clara, CA, USA). Gene expression differences >twofold were analysed using Genepattern software [26]. Gene Set Enrichment Analysis (GSEA) was performed using the c3_all and c5 collections in the Molecular Signatures Database (MSigDB) [27, 28]. Results were deposited in a public functional genomics data repository (Gene Expression Omnibus, www.ncbi.nlm.nih.gov/geo).
Immunoblotting
Tissues were homogenised in RIPA buffer (65 mmol/l Tris · HCl, 150 mmol/l NaCl, 5 mmol/l EDTA, 1% NP-40 [vol./vol.], 0.5% sodium deoxycholate [wt/vol.], 0.1% SDS [wt/vol.] and 10% glycerol [vol./vol.], pH 7.4) containing 1 mg/l aprotinin, 1 mg/l leupeptin, 10 mmol/l NaF, 1 mmol/l Na3VO4 and 1 mmol/l PMSF. Cleared lysates (20 μg protein) were electrophoresed in 10% polyacrylamide gels and transferred to PVDF membranes (GE Healthcare, Buckinghamshire, UK). Antibodies for stearoyl-CoA desaturase-1 (SCD1; 2438), fatty acid synthase (FAS; 3180), acetyl-CoA carboxylase (ACC; 36625) and acyl-CoA synthetase long-chain family member 1 (ACSL1; 4047) were obtained from Cell Signaling Technologies (Danvers, MA, USA). The sterol regulatory element-binding protein (SREBP1) antibody (MS1207P1ABX) was obtained from Thermo Scientific (Scoresby, VIC, Australia). Glucose 6-phosphatase (G6Pase) and 14-3-3 (sc-25840 and sc-629, respectively) antibodies were supplied by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Appropriate HRP-conjugated secondary antibodies were obtained from Jackson ImmunoResearch (West Grove, PA, USA). Densitometry was performed using ImageJ software.
Cytokine profiling
Plasma was collected at 4 and 10 weeks post-transplantation. Freshly thawed plasma was filtered using sterile Ultrafree-MC GV centrifuge filters (Millipore, Kilsyth, VIC, Australia) and cytokine concentrations were determined using a Bio-Plex Pro Mouse Cytokine Assay (M60-009RDPD) and a Bio-Plex 200 instrument (Bio-Rad, Hercules, CA, USA). The intra-assay CV for all cytokines was >5%.
Statistical analysis
All data are presented as mean ± SEM. Glucose excursions during the GTT were expressed as incremental AUC (iAUC), calculated using Microsoft Excel. Differences between groups were analysed by Student’s t test, one-way or two-way ANOVA (or their non-parametric equivalents) using GraphPad Prism (La Jolla, CA, USA). Multiple comparisons were corrected using the Holm–Sidak (parametric) or Dunn’s (non-parametric) tests. Relationships between continuous variables were assessed using Pearson’s or Spearman correlations, as appropriate. A two-sided p < 0.05 was considered significant.
Results
Glucose tolerance in SubQ → Vis mice was improved from 6 weeks post-transplantation
We previously reported beneficial effects of SubQ → Vis transplantation at 12–13 weeks [19]. Here, we studied HFD-fed Sham, SubQ → Vis and Vis → Vis mice for 3, 6 and 17 weeks (Fig. 1a). AT transplantation did not significantly affect body weight (Fig. 1b), fat mass (Fig. 1c) or lean mass (Fig. 1d). Masses of AT depots at 3, 6, and 17 weeks after transplantation are shown in Table 1. No significant differences in energy expenditure, RQ or food intake were observed (Electronic supplementary material [ESM] Table 1).
Glucose tolerance was sustainably improved in SubQ → Vis mice from 6 weeks onwards (Fig. 1e–i). At 7 weeks after transplantation, SubQ → Vis mice had the lowest basal and 15 min blood glucose concentrations during an ITT (Fig. 1j, k).
Grafted subcutaneous fat regresses, while grafted visceral fat expands intra-abdominally
Comparable amounts of AT were initially transplanted into SubQ → Vis and Vis → Vis mice, but over the 17 weeks, grafted inguinal SAT gradually reduced in mass, while grafted epididymal VAT expanded (Table 1 and Fig. 2a). Apoptosis was generally absent (ESM Fig. 1). SubQ → Vis grafts had smaller adipocytes than Vis → Vis grafts, particularly at 17 weeks (Fig. 2b–j); and Vis → Vis grafts expressed more leptin (data not shown). Plasma concentrations of leptin (Fig. 2k) and adiponectin (Fig. 2l) did not differ among groups.
Improved glucose tolerance in SubQ → Vis mice does not involve altered skeletal muscle or endogenous AT glucose uptake
Next, we investigated tissue-specific glucose uptake in chow-fed mice and HFD-fed Sham, SubQ → Vis and Vis → Vis mice at 13 weeks after transplantation. HFD feeding increased adiposity (Fig. 3a), worsened glucose tolerance (Fig. 3b, c) and increased fasting insulinaemia (Fig. 3d).
SubQ → Vis mice were completely protected against HFD-induced glucose intolerance (Fig. 3b, c); and transplantation of either type of AT significantly reduced fasting insulinaemia (Fig. 3d, e). Suppression of NEFA concentrations was used as a surrogate measure of AT insulin sensitivity: fasting and 120 min NEFA concentrations tended to be higher in HFD-fed Sham mice compared with the other groups (Fig. 3f). SubQ → Vis transplantation also reversed HFD-induced expression of the hepatic gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and G6Pase (Fig. 3g).
Glucose uptake into quadriceps muscle and endogenous AT (epididymal, inguinal, retroperitoneal, intrascapular brown) was blunted by HFD feeding but did not differ among HFD-fed Sham, SubQ → Vis and Vis → Vis mice (Fig. 3h). Grafted SAT and VAT displayed similar glucose uptake; however, when compared with their endogenous depots, glucose uptake was increased by 2.8-fold and 2.0-fold in SubQ → Vis and Vis → Vis grafts, respectively. Chronically increasing AT glucose uptake increases lactate release in the fed state and improves insulin sensitivity [29]: SubQ → Vis mice tended to have the highest postprandial plasma lactate concentrations at 17 weeks (ESM Fig. 2). Tracer incorporation into glycogen and triacylglycerol is shown in ESM Fig. 3.
Grafted and endogenous subcutaneous depots of SubQ → Vis mice display an induction of skeletal muscle-specific genes
To better understand the metabolic effects of SubQ → Vis transplantation, we compared gene expression in SAT implanted either intra-abdominally (SubQ → Vis) or subcutaneously (SubQ → SubQ) [19] (Fig. 4a). Twenty-eight genes displayed a >fivefold increase in expression in SubQ → Vis compared with SubQ → SubQ grafts (Fig. 4b); many were cytoskeletal components of skeletal muscle (Fig. 4c). GSEA identified a common transcription factor regulating 12 of these genes: myocyte enhancer factor 2A (MEF2A). MEF2 transcription factors have established roles in myogenesis, muscle metabolism, nervous system development/repair and more recently, immune response [30].
Remarkably, expression of many of these genes was also induced in the endogenous inguinal AT of SubQ → Vis mice, relative to Sham-operated mice (Fig. 4b). GSEA of endogenous inguinal AT revealed enrichment for genes related to RNA processing and immune responses (Fig. 4d). Mef2c and Mef2d were selectively induced in endogenous inguinal AT of SubQ → Vis mice (Fig. 4e); and SubQ → Vis mice had smaller adipocytes in this depot (Fig. 4f).
SubQ → Vis transplantation protects against HFD-induced hepatic triacylglycerol accumulation
AT transplantation has been previously reported to reduce HFD-induced hepatic triacylglycerol accumulation [21, 22]. At 17 weeks, hepatic triacylglycerol content was reduced in SubQ → Vis mice, relative to Vis → Vis mice, but no differences were observed at 6 weeks, when glucose tolerance was first improved (Fig. 5a). Hepatic glycogen content was unaffected (Fig. 5b).
Next, we measured the levels of the insulin-regulated lipogenic factor SREBP1 and its target genes (Fig. 5c–h). SREBP1 content and that of its target SCD1 tended to be highest in Vis → Vis mice (Fig. 5e, f), but the differences were not statistically significant. Levels of other SREBP targets, FAS, ACC and ACSL1, were not altered (Fig. 5g, h). Quadriceps muscle triacylglycerol content was significantly elevated in SubQ → Vis mice at 6 weeks after transplantation, but not at 17 weeks (Fig. 5i). Transplantation did not affect muscle glycogen content (Fig. 5j).
We also investigated gene expression using PCR arrays (ESM Fig. 4). Stat3 mRNA was elevated in livers from SubQ → Vis mice compared with Vis → Vis mice (p < 0.05), and tended to be higher than in livers from Sham mice (p = 0.056). Relative to Sham mice, Socs3, Adipor2, Lpl and Foxa2 mRNA were all significantly downregulated in livers from Vis → Vis mice. In human hepatocarcinoma cells, ADIPOR2 expression may be negatively regulated by SREBP1 [31].
SubQ → Vis transplantation reduced circulating markers of inflammation
Plasma cytokine profiling was also performed at 4 and 10 weeks after transplantation (Fig. 6 & ESM Tables 2 and 3). SubQ → Vis transplantation significantly attenuated HFD-induced increases in plasma concentrations of TNF-α, IL-6 and IL-17 (Fig. 6a–c). Plasma IL-6 concentrations were uniquely elevated in Vis → Vis mice at 10 weeks after transplantation (Fig. 6b). HFD feeding is associated with increased plasma concentrations of IL-12p70 and the chemokines monocyte chemotactic protein-1/chemokine (C-C) motif) ligand 5 (MCP-1/CCL5) and macrophage inflammatory protein-1 beta/chemokine (C-C) ligand 4 (MIP-1β/CCL4) [32–34]; all were significantly reduced in SubQ → Vis mice relative to Sham mice (Fig. 6d–f). Concentrations of the Th1 chemokine RANTES/CCL5 (regulated on activation, normal T cell expressed and secreted/chemokine (C-C) ligand 5) were suppressed in SubQ → Vis and Vis → Vis mice compared with Sham mice (Fig. 6g).
Th2 cells promote anti-inflammatory (M2) macrophage polarisation via the production of IL-4, IL-10 or IL-13 [35]. Plasma IL-10 and IL-4 concentrations were lower in SubQ → Vis mice than in Sham mice at 10 weeks (Fig. 6h, i). Transplantation of both types of AT suppressed plasma concentrations of IL-13, and those of the Th1 cytokines IL-5 and IL-2 (Fig. 6j–l).
Next, we examined relationships between the above cytokines and either the response to a GTT (iAUC GTT) or fasting insulinaemia at 13 weeks in chow or HFD-fed Sham, SubQ → Vis and Vis → Vis mice (n = 40). All cytokines in Fig. 6, except IL-6, predicted fasting insulinaemia (Fig. 7a); however, only TNF-α and IL-17 concentrations predicted both iAUC GTT and fasting insulinaemia (Fig. 7a–c). None of the cytokines measured at 4 weeks significantly predicted subsequent changes in glucose tolerance (data not shown).
Finally, to determine whether changes in AT gene expression influenced systemic cytokine concentrations, we examined the mRNA expression of Tnfa, Il6, Il17, Il12a, Ccl2, Ccl4 and Ccl5 in endogenous and grafted AT from our microarray data. Differences in plasma cytokine concentrations were not reflected in AT gene expression (Fig. 7d–j), and staining of SubQ → Vis and Vis → Vis grafts for F4/80, a marker of AT macrophages [36], did not reveal marked differences in macrophage content (ESM Fig. 5).
Discussion
Transplantation of inguinal, but not epididymal, AT uniquely and reproducibly protects mice against HFD-induced glucose intolerance and may reduce adiposity [19, 20]. Here, SubQ → Vis transplantation improved glucose tolerance at 6 weeks, and was not explained by differences in adiposity, leptin, adiponectin or tissue-specific glucose uptake. Instead, SubQ → Vis transplantation reduced hepatic triacylglycerol accumulation and normalised gluconeogenic enzyme expression. Reduced hepatic triacylglycerol content in SubQ → Vis mice was not present at 6 weeks, however, suggesting that this occurs subsequent to improved glucose tolerance. SubQ → Vis transplantation also suppressed HFD-induced systemic inflammation: plasma concentrations of TNF-α, IL-17, IL-12p70, MCP-1/CCL2 and MIP-1β/CCL4 were all significantly reduced in SubQ → Vis mice, relative to Sham mice. Plasma IL-17 and MIP-1β concentrations were reduced in SubQ → Vis mice as early as 4 weeks post-transplantation, possibly preceding improvements in glucose tolerance.
This study is the first to show anti-inflammatory effects of SubQ → Vis transplantation, although previous studies have suggested that Vis → Vis transplantation has proinflammatory effects [20, 37–39]. Immune cell composition differs between AT depots and is highly influenced by obesity [40]. In C57BL6/J mice, epididymal fat is skewed towards innate immunity, while the inguinal depot contains higher proportions of adaptive immune cells (CD4+ and CD8+ T cells and B cells) [40]. Obesity is characterised by an increase in proinflammatory Th1 cells, particularly in VAT [35]. SubQ → Vis transplantation likely prevents HFD-induced glucose intolerance and IR by altering the balance of these cell types specifically in the intra-abdominal compartment, as SubQ → SubQ transplantation does not affect glucose tolerance [19, 20]. While further studies will be required to fully understand how this procedure affects immune cell populations, it will be important to consider migration of cells from donor AT to other tissues, including liver and spleen, following transplantation [41]. We were unable to relate differences in plasma cytokine concentrations to mRNA expression in grafted or endogenous AT (Fig. 7).
The early differences in IL-17 concentrations, and their relationship with glucose intolerance and insulinaemia, support a role for T helper 17 (Th17) cells in the pathogenesis of HFD-induced IR. Th17 populations expand in obesity and are a major source of proinflammatory IL-17 [42]. Th17 expansion depends on IL-6 and leptin in the AT microenvironment [43]. Genetic deletion [44] or antibody-mediated neutralisation [45] of IL-17 prevents IR, glucose intolerance and liver injury in HFD-fed mice. Human studies also implicate IL-17 in the pathogenesis of IR [46, 47]. IL-17 may link AT inflammation with hepatic IR, as pre-treating human hepatocytes with IL-17 inhibited insulin-stimulated Akt phosphorylation and suppression of gluconeogenesis [16].
Beneficial effects of Vis → Vis transplantation (with caval drainage, not portal) on glucose tolerance have been reported at 4–8 weeks post-transplantation [18, 21, 39]. In the short term (≤6 weeks), this additional VAT may reduce endogenous adiposity (Table 1), and protect against lipotoxicity (Fig. 5); but these effects are not sustained. Relative to Sham mice, Vis → Vis transplantation reduces HFD-induced hyperinsulinaemia, elevates plasma IL-6 concentrations, but does not prevent glucose intolerance or hepatic triacylglycerol accumulation.
Subcutaneous AT transplantation reproducibly prevents HFD-induced glucose intolerance in mice. While the mechanisms are incompletely understood, we have identified sustained anti-inflammatory effects of this procedure that predicted metabolic improvements. Future studies will be required to identify the cell type(s) responsible, and potential sites of intervention for the treatment and prevention of diet-induced glucose intolerance and IR.
Abbreviations
- ACC:
-
Acetyl-CoA carboxylase
- ACSL1:
-
Acyl-CoA synthetase long-chain family member 1
- AT:
-
Adipose tissue
- DEXA:
-
Dual-energy x-ray absorptiometry
- EPI:
-
Endogenous epididymal AT
- FAS:
-
Fatty acid synthase
- GTT:
-
Glucose tolerance test
- GSEA:
-
Gene Set Enrichment Analysis
- G6Pase:
-
Glucose 6-phosphatase
- HFD:
-
High-fat diet
- iAUC:
-
Incremental AUC
- ING:
-
Endogenous inguinal AT
- IR:
-
Insulin resistance
- ITT:
-
Insulin tolerance test
- MCP-1/CCL2:
-
Monocyte chemotactic protein-1/chemokine (C-C motif) ligand 2
- MEF:
-
Myocyte enhancer factor
- MIP-1β/CCL4:
-
Macrophage inflammatory protein-1 beta/chemokine (C-C) ligand 4
- PEPCK:
-
Phosphoenolpyruvate carboxykinase
- RANTES/CCL5:
-
Regulated on activation, normal T cell expressed and secreted/ chemokine (C-C) ligand 5
- SAT:
-
Subcutaneous AT
- SCD1:
-
Stearoyl-CoA desaturase-1
- SREBP1:
-
Sterol regulatory element-binding protein
- SubQ → SubQ:
-
Subcutaneous → subcutaneous
- SubQ → Vis:
-
Subcutaneous → visceral
- VAT:
-
Visceral AT
- Vis → Vis:
-
Visceral → visceral
References
Kissebah AH, Krakower GR (1994) Regional adiposity and morbidity. Physiol Rev 74:761–811
Carr DB, Utzschneider KM, Hull RL et al (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087–2094
Bjorntorp P (1990) “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10:493–496
Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Invest 113:1582–1588
Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56:1010–1013
Manolopoulos KN, Karpe F, Frayn KN (2010) Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 34:949–959
Manolopoulos KN, Karpe F, Frayn KN (2012) Marked resistance of femoral adipose tissue blood flow and lipolysis to adrenaline in vivo. Diabetologia 55:3029–3037
Frayn KN (2002) Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:1201–1210
Pinnick KE, Nicholson G, Manolopoulos KN et al (2014) Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 63:3785–3797
Swarbrick MM (2014) A lifetime on the hips: programming lower-body fat to protect against metabolic disease. Diabetes 63:3575–3577
Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830
Sun S, Ji Y, Kersten S, Qi L (2012) Mechanisms of inflammatory responses in obese adipose tissue. Annu Rev Nutr 32:261–286
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808
Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175–184
Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18:363–374
Fabbrini E, Cella M, McCartney SA et al (2013) Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology 145(366–374):e361–e363
Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346–357
Konrad D, Rudich A, Schoenle EJ (2007) Improved glucose tolerance in mice receiving intraperitoneal transplantation of normal fat tissue. Diabetologia 50:833–839
Hocking SL, Chisholm DJ, James DE (2008) Studies of regional adipose transplantation reveal a unique and beneficial interaction between subcutaneous adipose tissue and the intra-abdominal compartment. Diabetologia 51:900–902
Tran TT, Yamamoto Y, Gesta S, Kahn CR (2008) Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 7:410–420
Foster MT, Shi H, Softic S, Kohli R, Seeley RJ, Woods SC (2011) Transplantation of non-visceral fat to the visceral cavity improves glucose tolerance in mice: investigation of hepatic lipids and insulin sensitivity. Diabetologia 54:2890–2899
Foster MT, Softic S, Caldwell J, Kohli R, de Kloet AD, Seeley RJ (2013) Subcutaneous adipose tissue transplantation in diet-induced obese mice attenuates metabolic dysregulation while removal exacerbates it. Physiol Rep 1:e00015
Hoehn KL, Turner N, Swarbrick MM et al (2010) Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab 11:70–76
Crosson SM, Khan A, Printen J, Pessin JE, Saltiel AR (2003) PTG gene deletion causes impaired glycogen synthesis and developmental insulin resistance. J Clin Invest 111:1423–1432
Lau SM, Cha KM, Karunatillake A et al (2013) Beta-cell ARNT is required for normal glucose tolerance in murine pregnancy. PLoS One 8:e77419
Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38:500–501
Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550
Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273
Munoz S, Franckhauser S, Elias I et al (2010) Chronically increased glucose uptake by adipose tissue leads to lactate production and improved insulin sensitivity rather than obesity in the mouse. Diabetologia 53:2417–2430
Clark RI, Tan SW, Pean CB et al (2013) MEF2 is an in vivo immune-metabolic switch. Cell 155:435–447
Reed BD, Charos AE, Szekely AM, Weissman SM, Snyder M (2008) Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes. PLoS Genet 4:e1000133
Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG (2008) Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8:301–309
Jiao P, Chen Q, Shah S et al (2009) Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes 58:104–115
Yepuru M, Eswaraka J, Kearbey JD et al (2010) Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem 285:31292–31303
Sell H, Habich C, Eckel J (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8:709–716
Bassaganya-Riera J, Misyak S, Guri AJ, Hontecillas R (2009) PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation. Cell Immunol 258:138–146
Ohman MK, Shen Y, Obimba CI et al (2008) Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:798–805
Nov O, Shapiro H, Ovadia H et al (2013) Interleukin-1beta regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS One 8:e53626
Rytka JM, Wueest S, Schoenle EJ, Konrad D (2011) The portal theory supported by venous drainage-selective fat transplantation. Diabetes 60:56–63
Caspar-Bauguil S, Cousin B, Galinier A et al (2005) Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett 579:3487–3492
Paz-Filho G, Mastronardi CA, Parker BJ et al (2013) Molecular pathways involved in the improvement of non-alcoholic fatty liver disease. J Mol Endocrinol 51:167–179
Winer S, Paltser G, Chan Y et al (2009) Obesity predisposes to Th17 bias. Eur J Immunol 39:2629–2635
Chuang HC, Sheu WH, Lin YT et al (2014) HGK/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance. Nat Commun 5:4602
Zuniga LA, Shen WJ, Joyce-Shaikh B et al (2010) IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 185:6947–6959
Harley IT, Stankiewicz TE, Giles DA et al (2014) IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 59:1830–1839
Jagannathan-Bogdan M, McDonnell ME, Shin H et al (2011) Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 186:1162–1172
Goossens GH, Blaak EE, Theunissen R et al (2012) Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol 50:142–149
Acknowledgements
The authors would like to thank P. Lee, S. Grey and W. Kaplan (Garvan Institute) for their constructive comments on the manuscript, as well as the staff of the Garvan Institute Histopathology (A. Boulghourjian and A. Zaratzian) and Biological Testing Facilities. These results were presented at the 2014 Australian and New Zealand Obesity Society (ANZOS) Annual Scientific Meeting in Sydney, Australia.
Funding
This work was supported by project (to MMS, SLH and AEB) and program (to DEJ and GJC) grants from the National Health and Medical Research Council (NHMRC) of Australia.
Duality of interest
EK, SPB and MM are paid employees of Regeneus, Ltd. BRH is a nonexecutive director and paid consultant of Regeneus, Ltd. SPB, MM and BRH are shareholders in Regeneus Ltd. Regeneus Ltd did not provide funding for any of the experiments detailed in this manuscript. GAK, ZM and JRJ are employees of and shareholders in Genentech, Inc.
Contribution statement
All authors made substantial contributions to the conception and design of the various aspects of the prospective studies or to the acquisition, analysis or interpretation of data. All authors also contributed to drafting the article or revising it critically for important intellectual content and have given final approval of the version to be published. MMS and SLH are responsible for the integrity of this work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM Fig. 1
(PDF 4.45 mb)
ESM Fig. 2
(PDF 53 kb)
ESM Fig. 3
(PDF 569 kb)
ESM Fig. 4
(PDF 1814 kb)
ESM Fig. 5
(PDF 24468 kb)
ESM Table 1
(PDF 90 kb)
ESM Table 2
(PDF 94 kb)
ESM Table 3
(PDF 95 kb)
Rights and permissions
About this article
Cite this article
Hocking, S.L., Stewart, R.L., Brandon, A.E. et al. Subcutaneous fat transplantation alleviates diet-induced glucose intolerance and inflammation in mice. Diabetologia 58, 1587–1600 (2015). https://doi.org/10.1007/s00125-015-3583-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-015-3583-y